Gilead Sciences (GILD) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY26 Guidance

Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.03, $0.13 better than the analyst estimate of $1.90. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.91 billion.

GUIDANCE:

Gilead Sciences sees FY2026 EPS of ($1.05)-($0.65), versus the consensus of $8.65. Gilead Sciences sees FY2026 revenue of $30-30.4 billion, versus the consensus of $30.2 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c